We now are witnessing an expansion of government enforcement programs and laboratory types affected. While much of the action continues to involve toxicology facilities receiving federal and state funds, today we are also observing intervention against laboratories offering genetic testing and receiving reimbursement from commercial sources. In the latest installment of the video blog “Dr. Daly Discusses…,” COLA’s Chief Medical Officer Dr. John Daly discusses how clinical laboratories continue to be the subject of federal anti-fraud action.

About The Author

Prior to his role as Chief Medical Officer at COLA, Dr. John Daly was the Director of Clinical Laboratories for the Duke University Health System from 2005-2009. A longtime resident of Durham, NC, Dr. Daly was quite active in the local medical community, joining the staffs of three area hospitals and serving as a member of various hospital committees. He earned his M. D. at Cornell University Medical College, and performed his internship and residency in pathology at Duke University Medical Center. He also is a veteran of the U. S. Navy.